Cabergoline
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
- Cabergoline
- Pharmacist Assessment Report
- Cabergoline: dopamine D2 receptor agonist → progeria-short stature-pigmented nevi syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cabergoline: dopamine D2 receptor agonist → progeria-short stature-pigmented nevi syndrome
One-Sentence Summary
Cabergoline is a dopamine receptor agonist that is marketed in Australia as Dostinex tablets. The TxGNN model predicts it may be relevant to progeria-short stature-pigmented nevi syndrome, but this is a computational prediction only. No clinical trials and no publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | progeria-short stature-pigmented nevi syndrome |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Cabergoline is generally understood to act as a dopamine D2 receptor agonist.
No plausible dopaminergic mechanism is evident for this rare syndrome. The high TxGNN score reflects a computational pattern only. It has not been supported by any mechanistic study, clinical trial or publication, so the prediction should be treated as a hypothesis for exploration, not as a reasoned repurposing case.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| Licence Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 13901P | Dostinex | Tablet 500 micrograms (oral) | Not recorded in the local data |
The one licence on record is a valid single-ingredient product.
Safety Considerations
- Drug Interactions: 60 interactions were identified in the data compiled for this report. The main ones are:
- Major: lorcaserin and clarithromycin.
- Moderate: metoclopramide.
- Many other interactions are of unknown severity (for example, proton pump inhibitors, corticosteroids, metformin and simvastatin).
No label-based warnings or contraindications are available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone (Evidence Level L5). There are no trials, no literature and no plausible mechanistic link to support progeria-short stature-pigmented nevi syndrome.
To proceed, the following is needed:
- A documented biological rationale linking dopamine D2 signalling to this syndrome
- Any preclinical or clinical studies that directly address this condition
- Mechanism of action data for cabergoline and its safety information from the TGA Product Information
- An assessment of the risk-benefit balance in this rare patient population, given the interaction profile and the lack of any efficacy data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.